SIRPA and rheumatoid arthritis: In conclusion we have identified a predictive marker present prior to adalimumab treatment that it is associated with the development of antibodies against adalimumab in patients with RA; specifically, a frequency of < 9.4% of SIRPα/β+memory B cells.